We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
What does a modified-Fibonacci dose-escalation actually correspond to?
- Authors
Penel, Nicolas; Kramar, Andrew
- Abstract
Background: In most phase I oncology trials, it is often stated that the dose increments follow a "modified- Fibonacci sequence". This term, however, is vague. Methods: To better characterize this sequence, we reviewed 81 phase I trials based on this concept. Results: Out of 198 phase I oncology trials, 81 (41%) are based on modified-Fibonacci series. Actual incremental ratios varied in a large range from 0.80 to 2.08. The median of actual increments was about 2.00, 1.50, 1.33, 1.33, 1.33, 1.33, 1.30, 1.35.... The "modified Fibonacci-sequence" gathers heterogeneous variation of the genuine sequence, which does not tend to a constant number at higher dose-levels. Conclusion: This confusing term should be avoided.
- Subjects
ONCOLOGY; TUMORS; CYSTS (Pathology); PATHOLOGY; CANCER
- Publication
BMC Medical Research Methodology, 2012, Vol 12, Issue 1, p103
- ISSN
1471-2288
- Publication type
Article
- DOI
10.1186/1471-2288-12-103